利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.026 秒)

    Fucose transporter
    1.
    发明申请
    Fucose transporter 失效
    岩藻糖转运蛋白

    公开(公告)号：US20060246456A1

    公开(公告)日：2006-11-02

    申请号：US10561191

    申请日：2004-06-18

    申请人： Masayuki Tsuchiya ,  Shigeyuki Iijima ,  Izumi Sugo ,  Yasuo Sekimori ,  Kenju Ueno ,  Kiyoshi Habu

    发明人： Masayuki Tsuchiya ,  Shigeyuki Iijima ,  Izumi Sugo ,  Yasuo Sekimori ,  Kenju Ueno ,  Kiyoshi Habu

    IPC分类号： C12Q1/68 ,  G01N33/53 ,  C07H21/04 ,  C12P21/06 ,  C07K16/28 ,  C07K14/705

    CPC分类号： C07K14/47 ,  C12P21/005 ,  G01N2500/00

    摘要： The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited. The present invention further relates to a method for producing recombinant protein, and specifically, to a method for producing protein by which fucose existing within the Golgi apparatus of a host cell is decreased, a method for inhibiting the addition of fucose to protein by which fucose existing within the Golgi apparatus of a host cell is decreased upon production of recombinant protein using the host cell, a method for increasing the cytotoxic activity of an antibody by which an antibody is produced using a cell wherein fucose existing within the Golgi apparatus is decreased, and a cell having a Golgi apparatus wherein fucose existing within the Golgi apparatus is decreased.

    摘要翻译： 本发明提供了编码岩藻糖转运蛋白，岩藻糖转运蛋白多肽，筛选结合岩藻糖转运蛋白的化合物或抑制岩藻糖转运活性的化合物的方法，具有抑制岩藻糖转运蛋白功能的细胞的基因，以及细胞，其中 岩藻糖转运蛋白的表达被抑制。 本发明还涉及一种生产重组蛋白的方法，具体地说涉及一种生物蛋白质的制造方法，其中存在于宿主细胞高尔基体内的岩藻糖减少，一种抑制岩藻糖加入蛋白质的方法，通过该方法将岩藻糖 在使用宿主细胞产生重组蛋白质时，存在于宿主细胞的高尔基体内的存在的方法，使用其中存在于高尔基体中的岩藻糖减少的细胞增加抗体产生抗体的方法， 和具有高尔基体的细胞，其中存在于高尔基体内的岩藻糖减少。

    Fucose transporter
    2.
    发明授权
    Fucose transporter 失效
    岩藻糖转运蛋白

    公开(公告)号：US07863042B2

    公开(公告)日：2011-01-04

    申请号：US10561191

    申请日：2004-06-18

    申请人： Masayuki Tsuchiya ,  Shigeyuki Iijima ,  Izumi Sugo ,  Yasuo Sekimori ,  Kenju Ueno ,  Kiyoshi Habu

    发明人： Masayuki Tsuchiya ,  Shigeyuki Iijima ,  Izumi Sugo ,  Yasuo Sekimori ,  Kenju Ueno ,  Kiyoshi Habu

    IPC分类号： C07H17/00

    CPC分类号： C07K14/47 ,  C12P21/005 ,  G01N2500/00

    摘要： The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited. The present invention further relates to a method for producing recombinant protein, and specifically, to a method for producing protein by which fucose existing within the Golgi apparatus of a host cell is decreased, a method for inhibiting the addition of fucose to protein by which fucose existing within the Golgi apparatus of a host cell is decreased upon production of recombinant protein using the host cell, a method for increasing the cytotoxic activity of an antibody by which an antibody is produced using a cell wherein fucose existing within the Golgi apparatus is decreased, and a cell having a Golgi apparatus wherein fucose existing within the Golgi apparatus is decreased.

    摘要翻译： 本发明提供了编码岩藻糖转运蛋白，岩藻糖转运蛋白多肽，筛选结合岩藻糖转运蛋白的化合物或抑制岩藻糖转运活性的化合物的方法，具有抑制岩藻糖转运蛋白功能的细胞的基因，以及细胞，其中 岩藻糖转运蛋白的表达被抑制。 本发明还涉及一种生产重组蛋白的方法，具体地说涉及一种产生蛋白质的方法，通过该方法，存在于宿主细胞高尔基体内的岩藻糖减少，一种抑制岩藻糖加入岩藻糖蛋白质的方法 在使用宿主细胞产生重组蛋白质时，存在于宿主细胞的高尔基体内的存在的方法，使用其中存在于高尔基体中的岩藻糖减少的细胞增加抗体产生抗体的方法， 和具有高尔基体的细胞，其中存在于高尔基体内的岩藻糖减少。

    SGRF GENE-MODIFIED MOUSE
    5.
    发明申请
    SGRF GENE-MODIFIED MOUSE 有权
    SGRF基因修饰鼠

    公开(公告)号：US20090288177A1

    公开(公告)日：2009-11-19

    申请号：US12499694

    申请日：2009-07-08

    申请人： Kiyoshi Habu ,  Yuichi Hirata

    发明人： Kiyoshi Habu ,  Yuichi Hirata

    IPC分类号： A01K67/027

    CPC分类号： A01K67/0276 ,  A01K67/0271 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0325 ,  A01K2267/0368 ,  C12N15/8509 ,  C12N2800/30

    摘要： A targeting vector was constructed by replacing exon regions in the SGRF gene with appropriate drug marker genes. This vector was transfected into mouse ES cell lines to obtain chimeric mice, which were then crossed with C57BL/6J mice to obtain mice comprising cells in which one SGRF gene alleles was inactivated. By crossing these mice with each other, the present inventors succeeded in producing mice in which both SGRF gene alleles were inactivated. These genetically modified animals can be used to predict the side effects of drugs such as SGRF antagonists.

    摘要翻译： 通过用适当的药物标记基因取代SGRF基因中的外显子区域构建靶向载体。 将该载体转染入小鼠ES细胞系以获得嵌合小鼠，然后将其与C57BL / 6J小鼠杂交，以获得包含其中一个SGRF基因等位基因被灭活的细胞的小鼠。 通过使这些小鼠相互交叉，本发明人成功地生产了两种SGRF基因等位基因都被灭活的小鼠。 这些转基因动物可用于预测药物如SGRF拮抗剂的副作用。

    SGRF gene-modified mouse
    7.
    发明授权
    SGRF gene-modified mouse 有权
    SGRF基因修饰小鼠

    公开(公告)号：US07829757B2

    公开(公告)日：2010-11-09

    申请号：US12499694

    申请日：2009-07-08

    申请人： Kiyoshi Habu ,  Yuichi Hirata

    发明人： Kiyoshi Habu ,  Yuichi Hirata

    IPC分类号： G01N33/00

    CPC分类号： A01K67/0276 ,  A01K67/0271 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0325 ,  A01K2267/0368 ,  C12N15/8509 ,  C12N2800/30

    摘要： A targeting vector was constructed by replacing exon regions in the SGRF gene with appropriate drug marker genes. This vector was transfected into mouse ES cell lines to obtain chimeric mice, which were then crossed with C57BL/6J mice to obtain mice comprising cells in which one SGRF gene alleles was inactivated. By crossing these mice with each other, the present inventors succeeded in producing mice in which both SGRF gene alleles were inactivated. These genetically modified animals can be used to predict the side effects of drugs such as SGRF antagonists.

    摘要翻译： 通过用适当的药物标记基因取代SGRF基因中的外显子区域构建靶向载体。 将该载体转染入小鼠ES细胞系以获得嵌合小鼠，然后将其与C57BL / 6J小鼠杂交，以获得包含其中一个SGRF基因等位基因被灭活的细胞的小鼠。 通过使这些小鼠相互交叉，本发明人成功地生产了两种SGRF基因等位基因都被灭活的小鼠。 这些转基因动物可用于预测药物如SGRF拮抗剂的副作用。

    Expression systems using mammalian beta-actin promoter
    8.
    发明授权
    Expression systems using mammalian beta-actin promoter 失效
    使用哺乳动物β-肌动蛋白启动子的表达系统

    公开(公告)号：US08298816B2

    公开(公告)日：2012-10-30

    申请号：US10581183

    申请日：2004-12-03

    申请人： Hiroyuki Tsunoda ,  Kiyoshi Habu

    发明人： Hiroyuki Tsunoda ,  Kiyoshi Habu

    IPC分类号： C12N15/00 ,  C12N5/00 ,  C12P21/06

    CPC分类号： G06Q50/22 ,  A01K2217/05 ,  C07K14/82 ,  C12N15/85 ,  C12N2830/00 ,  C12N2830/48 ,  C12N2830/85 ,  Y02A90/22

    摘要： Promoter activities were examined by comparing combinations of promoters and enhancers derived from various genes. A hybrid promoter comprising a combination of a CMV enhancer and a mammalian β-actin promoter, or the post-transcriptional regulatory region of the genomic sequence Woodchuck Hepatitis Virus (WPRE) and a mammalian β-actin promoter was found to be stronger than existing promoters. Furthermore, the activities of the β-actin promoters could be enhanced by coexpressing the oncogene product Ras, which is a transactivator.

    摘要翻译： 通过比较来自各种基因的启动子和增强子的组合来检查启动子活性。 发现包含CMV增强子和哺乳动物 - 肌动蛋白启动子或基因组序列Woodchuck Hepatitis Virus（WPRE）的转录后调控区和哺乳动物和肌动蛋白启动子的组合的杂合启动子比 现有发起人。 此外，可以通过共表达作为反式激活因子的致癌基因产物Ras来增强促进剂的活性。

    Method for Identifying Within a Mammal a DNA Encoding A Physiologically Active Polypeptide
    9.
    发明申请
    Method for Identifying Within a Mammal a DNA Encoding A Physiologically Active Polypeptide 审中-公开
    用于在哺乳动物中识别编码生理活性多肽的DNA的方法

    公开(公告)号：US20100329988A1

    公开(公告)日：2010-12-30

    申请号：US12858960

    申请日：2010-08-18

    申请人： Kiyoshi Habu ,  Kou-ichi Jishage ,  Hiroshi Suzuki

    发明人： Kiyoshi Habu ,  Kou-ichi Jishage ,  Hiroshi Suzuki

    IPC分类号： A61K49/00 ,  A61P43/00

    CPC分类号： A01K67/0275 ,  A01K67/0271 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/53 ,  C12N15/1034 ,  G01N33/5088

    摘要： The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance.

    摘要翻译： 本发明人发现，在引入了各种量的各种DNA的小鼠中，可以独立地检测特定DNA的生理作用。 该发现表明，可以通过使用哺乳动物中看到的特定生理效应作为指标，以各种量依次分级各种DNA的池来鉴定具有特定生理效应的DNA。 这种筛选方法将具有如常规筛选（例如使用转基因和敲除小鼠的筛选）所需的大量时间和精力的优点。 此外，筛选方法具有能够鉴定具有生理活性的DNA的额外优点，例如即使当生产生理活性物质的细胞不能在体外或免疫缺陷动物中维持时，或者当细胞改变其 特性在通过和停止生产生理活性物质。

    Method for Identifying Within a Mammal a DNA encoding a Physiologically Active Polypeptide
    10.
    发明申请
    Method for Identifying Within a Mammal a DNA encoding a Physiologically Active Polypeptide 审中-公开
    用于在哺乳动物体内鉴定编码生理活性多肽的DNA的方法

    公开(公告)号：US20090092995A1

    公开(公告)日：2009-04-09

    申请号：US12327770

    申请日：2008-12-03

    申请人： Kiyoshi Habu ,  Kou-Ichi Jishage ,  Hiroshi Suzuki

    发明人： Kiyoshi Habu ,  Kou-Ichi Jishage ,  Hiroshi Suzuki

    IPC分类号： C12Q1/68

    CPC分类号： A01K67/0275 ,  A01K67/0271 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/53 ,  C12N15/1034 ,  G01N33/5088

    摘要： The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance.

    摘要翻译： 本发明人发现，在引入了各种量的各种DNA的小鼠中，可以独立地检测特定DNA的生理作用。 该发现表明，可以通过使用哺乳动物中看到的特定生理效应作为指标，以各种量依次分级各种DNA的池来鉴定具有特定生理效应的DNA。 这种筛选方法将具有如常规筛选（例如使用转基因和敲除小鼠的筛选）所需的大量时间和精力的优点。 此外，筛选方法具有能够鉴定具有生理活性的DNA的额外优点，例如即使当生产生理活性物质的细胞不能在体外或免疫缺陷动物中维持时，或者当细胞改变其 特性在通过和停止生产生理活性物质。